Physician profile
Li Cai
NPI 1902860612
$9,538.13
in general payments reported to CMS, 2019-2025
41 companies · $1,351 in 2025
The $1,351 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $44.15 · 2021: $2,997 · 2022: $1,434 · 2023: $1,982 · 2024: $1,730 · 2025: $1,351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,063.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,062.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,438.04 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Biohaven Pharmaceuticals, INC. | $1,437.22 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $957.86 | 2021-2025 | Jardiance, Synjardy, Trijardy Xr |
| Amgen INC. | $660.47 | 2021-2025 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $456.31 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $440.39 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $417.84 | 2021-2025 | |
| Lilly USA, LLC | $343.57 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $331.44 | 2020-2025 | Farxiga, Breztri |
| Abbott Laboratories | $319.10 | 2023 | Freestyle Libre 3, Eterna, Prodigy |
| Janssen Pharmaceuticals, INC | $312.05 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $261.48 | 2021-2025 | Xifaxan, Trulance |
| Pfizer INC. | $228.13 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $215.87 | 2023-2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $211.58 | 2021-2025 | Gardasil 9, Capvaxive, Pneumovax 23 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Li Cai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.